Based on preclinical studies, EMPLICITI directly activates Natural Killer Cells via SLAMF7 and tags myeloma cells for destruction through ADCC1
ADCC=antibody-dependent cellular cytotoxicity; SLAMF7=signaling lymphocytic activation molecule family member 7.
PFSHR 0.70 [95% CI, 0.57, 0.85]; P=0.0004
Median PFS 19.4 months with ERd [95% CI, 16.6, 22.2] vs 14.9 months with Rd [95% CI, 12.1, 17.2]1
ORR78.5% with ERd [95% CI, 73.6, 82.9] vs
65.5% with Rd [95% CI, 60.1, 70.7]; P=0.0002
*Interim analysis conducted with a minimum follow-up of
EMPLICITI with lenalidomide and dexamethasone is
associated with the following Warnings and Precautions:
Infusion Reactions, Infections, Second Primary Malignancies,
Hepatotoxicity, Interference with Determination
of Complete Response, Pregnancy/Females and Males
of Reproductive Potential, and Adverse Reactions.
Please see detailed Important Safety Information below.
for the treatment of multiple myeloma
approved for use in combination with Rd in
patients who have received 1 to 3
the efficacy and safety of EMPLICITI in combination with Rd
in 646 patients (EMPLICITI + Rd, n=321; Rd, n=325) with multiple
myeloma who had received 1 to 3 prior therapies.1
ERd=EMPLICITI + lenalidomide + dexamethasone;
Rd=lenalidomide + dexamethasone.